Versor Investments LP Acquires 8,965 Shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Versor Investments LP raised its stake in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 93.4% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 18,565 shares of the medical equipment provider’s stock after acquiring an additional 8,965 shares during the quarter. Versor Investments LP’s holdings in Zimmer Biomet were worth $2,004,000 as of its most recent SEC filing.

A number of other hedge funds also recently made changes to their positions in the stock. Crewe Advisors LLC bought a new stake in shares of Zimmer Biomet during the first quarter worth $31,000. Ashton Thomas Securities LLC bought a new stake in Zimmer Biomet during the 3rd quarter worth $28,000. J.Safra Asset Management Corp increased its holdings in Zimmer Biomet by 712.1% in the 1st quarter. J.Safra Asset Management Corp now owns 268 shares of the medical equipment provider’s stock worth $35,000 after purchasing an additional 235 shares in the last quarter. Bangor Savings Bank acquired a new position in Zimmer Biomet in the 3rd quarter worth about $31,000. Finally, Family Firm Inc. bought a new position in Zimmer Biomet in the second quarter valued at about $33,000. 88.89% of the stock is currently owned by institutional investors and hedge funds.

Zimmer Biomet Trading Up 0.7 %

Shares of ZBH stock traded up $0.74 during trading hours on Monday, hitting $108.92. 149,844 shares of the company were exchanged, compared to its average volume of 1,484,608. The company has a debt-to-equity ratio of 0.38, a quick ratio of 0.70 and a current ratio of 1.36. Zimmer Biomet Holdings, Inc. has a fifty-two week low of $101.47 and a fifty-two week high of $133.90. The company has a 50 day simple moving average of $106.37 and a two-hundred day simple moving average of $110.33. The firm has a market cap of $21.68 billion, a P/E ratio of 20.57, a P/E/G ratio of 1.99 and a beta of 1.02.

Zimmer Biomet (NYSE:ZBH) last posted its quarterly earnings results on Wednesday, October 30th. The medical equipment provider reported $1.74 EPS for the quarter, hitting analysts’ consensus estimates of $1.74. Zimmer Biomet had a net margin of 14.27% and a return on equity of 12.95%. The business had revenue of $1.82 billion during the quarter, compared to analysts’ expectations of $1.80 billion. During the same period last year, the company posted $1.65 earnings per share. The business’s quarterly revenue was up 4.1% on a year-over-year basis. Equities analysts anticipate that Zimmer Biomet Holdings, Inc. will post 7.99 EPS for the current year.

Zimmer Biomet Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Thursday, October 31st. Investors of record on Monday, September 30th were paid a dividend of $0.24 per share. This represents a $0.96 dividend on an annualized basis and a yield of 0.88%. The ex-dividend date was Monday, September 30th. Zimmer Biomet’s dividend payout ratio (DPR) is currently 18.25%.

Analysts Set New Price Targets

ZBH has been the subject of several recent research reports. Canaccord Genuity Group lowered their price objective on Zimmer Biomet from $120.00 to $115.00 and set a “hold” rating for the company in a research note on Tuesday, September 10th. Robert W. Baird decreased their price target on shares of Zimmer Biomet from $155.00 to $145.00 and set an “outperform” rating for the company in a research report on Thursday, August 8th. Raymond James cut their price target on shares of Zimmer Biomet from $128.00 to $123.00 and set an “outperform” rating on the stock in a report on Monday, October 14th. Wells Fargo & Company increased their price objective on Zimmer Biomet from $110.00 to $117.00 and gave the company an “equal weight” rating in a report on Thursday, October 31st. Finally, Evercore ISI cut their target price on Zimmer Biomet from $113.00 to $110.00 and set an “in-line” rating on the stock in a report on Tuesday, October 1st. Two investment analysts have rated the stock with a sell rating, twelve have assigned a hold rating and eight have given a buy rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Hold” and an average price target of $124.11.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.